ProjectDAPT-Shock AMI – Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionDAPT-SHOCK-AMI study
Basic data
Acronym:
DAPT-Shock AMI
Title:
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionDAPT-SHOCK-AMI study
Duration:
01/06/2022 to 31/12/2024
Abstract / short description:
Objective: Comparison of the effect of parenteral Cangrelor with the recommended treatment with Ticagrelor to:
1) adenosine diphosphate (ADP) activated platelet aggregation, and
2) occurrence of major cardiovascular events
in patients with acute myocardial infarction, initially in cardiogenic shock.
Study population: Cardiogenic shock complicating acute myocardial infarction
Intervention: Cangrelor IV initially on the top of standard antiplatelet therapy
Primary endpoint – laboratory: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on adenosine diphosphate activated platelet aggregation.
Primary endpoint – clinical: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on the incidence of major cardiovascular events (Death, Myocardial Infarction, or Stroke) in patients with acute myocardial infarction initially in cardiogenic shock 30 days after enrolment in the study.
1) adenosine diphosphate (ADP) activated platelet aggregation, and
2) occurrence of major cardiovascular events
in patients with acute myocardial infarction, initially in cardiogenic shock.
Study population: Cardiogenic shock complicating acute myocardial infarction
Intervention: Cangrelor IV initially on the top of standard antiplatelet therapy
Primary endpoint – laboratory: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on adenosine diphosphate activated platelet aggregation.
Primary endpoint – clinical: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on the incidence of major cardiovascular events (Death, Myocardial Infarction, or Stroke) in patients with acute myocardial infarction initially in cardiogenic shock 30 days after enrolment in the study.
Involved staff
Managers
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen
University of Tübingen
Other staff
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Prag, Czechia
Cooperations
Prag, Czechia